D. Post‐Munson

发表

B‐973, a novel piperazine positive allosteric modulator of the &agr;7 nicotinic acetylcholine receptor

J. Macor, J. Herrington, M. Ahlijanian, 2017, European journal of pharmacology.

Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists.

J. Macor, S. Dworetzky, D. Post‐Munson, 2013, Bioorganic & medicinal chemistry letters.

Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.

M. D. Hill, J. Macor, Yulia Benitex, 2017, ACS medicinal chemistry letters.

Effects of channel modulators on cloned large-conductance calcium-activated potassium channels.

V. Gribkoff, J. T. Lum-Ragan, N. Meanwell, 1996, Molecular pharmacology.

Synthesis and structure-activity relationships of 3-aryloxindoles: a new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties.

V. Gribkoff, Stella Huang, N. Meanwell, 2002, Journal of medicinal chemistry.

Reduced bicuculline response and GABAA agonist binding in aged rat hippocampus

V. Gribkoff, J. T. Lum-Ragan, D. Post‐Munson, 1994, Neurobiology of Aging.

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2018, Journal of medicinal chemistry.

The synthesis and characterization of BMS-204352 (MaxiPost) and related 3-fluorooxindoles as openers of maxi-K potassium channels.

V. Gribkoff, R. Perrone, N. Meanwell, 2002, Bioorganic & medicinal chemistry letters.

Phenotypic Alteration of a Human BK (hSlo) Channel byhSloβ Subunit Coexpression: Changes in Blocker Sensitivity, Activation/Relaxation and Inactivation Kinetics, and Protein Kinase A Modulation

V. Gribkoff, J. T. Lum-Ragan, S. Dworetzky, 1996, The Journal of Neuroscience.

Synthesis and excitatory amino acid pharmacology of some novel quinoxalinediones

V. Gribkoff, N. Meanwell, D. Post‐Munson, 1993 .

Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels

Astrid A. Ortiz, P. Molinoff, V. Gribkoff, 2001, Nature Medicine.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia

J. Macor, Yulia Benitex, D. Post‐Munson, 2016, PloS one.

Effects of BMS‐902483, an &agr;7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents

Y. Asaka, J. Macor, J. Herrington, 2017, European journal of pharmacology.

A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site

D. Langley, J. Herrington, M. Ahlijanian, 2017, Molecular Pharmacology.

Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534

J. Macor, D. Post‐Munson, T. Molski, 2013, Neuropharmacology.

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2017, Journal of medicinal chemistry.

Development of spiroguanidine-derived α7 neuronal nicotinic receptor partial agonists.

Ping Chen, J. Macor, Yulia Benitex, 2017, Bioorganic & medicinal chemistry letters.

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2017, Journal of medicinal chemistry.

A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site

D. Langley, J. Herrington, M. Ahlijanian, 2017, Molecular Pharmacology.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.